Effectiveness of new drug-resistant TB treatment is maintained with ↓ dosage & duration of Linezolid

Dr Conor Tweed, Honorary Clinical Lecturer, MRC Clinical Trials Unit at UCL is in conversation with CNS founding Managing Editor and Executive Director Shobha Shukla. Jessica Wiggs, Senior Communication Specialist of TB Alliance (Global Alliance of TB Drug Development, www.TBalliance.org) joins the conversation.
Drug-Resistant TB Trial Results Published in New England Journal of Medicine | Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing and Duration of Linezolid | The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen. Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid. The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were published recently in the New England Journal of Medicine.
Thanks
CNS team